Compass Therapeutics, Inc.

Home
United States
Boston, MA
Compass Therapeutics, Inc.

We’re building Compass with a singular goal in mind: unlocking the complexity of the immune system. Compass Therapeutics, Inc.

is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis and the immune system. The company pipeline includes novel product candidates that leverage understanding of the tumor microenvironement, including both angiogenesis-targeted agent

s and immune-oncology focused agents. These product candidates are designed to optimize critical components required for an effective anti-tumor response to cancer. These include modulation of the microvasculature via angiogenesis-targeted agents; induction of a potent immune response via activators on effector cells in the tumor microenvironment; and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with its proprietary drug candidates as long as continued development is supported by clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. To learn more, visit www.compasstherapeutics.com

05/19/2026

Watch Compass Therapeutics CEO Thomas Schuetz, MD, PhD, present live at the 2026 Stifel Virtual Targeted Oncology Forum.

• Date: Wednesday, May 20, 2026
• Time: 11:30 a.m. ET

➜ Register now: cmpx.info/stifel

05/18/2026

Join Thomas Schuetz, MD, PhD, CEO of Compass Therapeutics, for a live webcast at the H.C. Wainwright 4th Annual BioConnect Investor Conference.

• Date: Tuesday, May 19, 2026
• Time: 12:00 p.m. ET

➜Register now: cmpx.info/hcw

05/05/2026

We were proud to attend the Cholangiocarcinoma Foundation 2026 Annual Conference in Salt Lake City, May 1–3, joining CCF in celebrating its 20th anniversary and honoring the cholangiocarcinoma community.

The conference brought together patients, caregivers, advocates, clinicians, researchers, and industry colleagues for important conversations about advancing research and care for patients with biliary tract cancer.

Congratulations to CCF on 20 years of leadership, support, and impact.

03/11/2026

Over the weekend was International Women’s Day and today we want to share our appreciate for the incredible women advancing innovation in science!

From the lab to the clinic, their leadership, skill, and dedication help drive our mission to develop new therapies for people living with cancer.

02/11/2026

Join us in welcoming Craig Bodycombe to Compass as Director of Analytical Development.

Craig brings 20 years of progressive experience in the biotechnology and pharmaceutical industries, specializing in protein therapeutics, including more than 10 years working with monoclonal antibodies.

02/03/2026

Cholangiocarcinoma (CCA) Awareness Month reminds us of the progress made—and the work that remains.

CCA is an aggressive cancer with significant unmet need—especially for patients facing advanced disease.

At Compass Therapeutics, we’re focused on translating science into meaningful progress for patients, including those facing hard-to-treat cancers. We are proud to stand with the Cholangiocarcinoma Foundation, honoring the entire CCA community—patients, caregivers, clinicians, researchers, and advocates—who keep moving forward, together. To learn more, visit: https://ow.ly/qeAq50Y7V2K

01/21/2026

Please welcome Varsha Menon to the Compass team as our Director of Biometrics!

Varsha brings deep experience as a Biometrics Lead, Oncology TA partner, and in patient advocacy.

01/13/2026

Join us at the 44th Annual J.P. Morgan Healthcare Conference for a live presentation and webcast with Thomas Schuetz, MD, PhD, CEO of Compass Therapeutics.

Location: San Francisco
Date: Wednesday, January 14, 2026
Time: 7:30–8:10 a.m. PT

Register now to watch live or on demand at cmpx.info/jpmorgan.

01/06/2026

Compass Therapeutics announces the appointments of Arjun Prasad, MBA, MPH, as Chief Commercial Officer, and Cynthia Sirard, MD, as Chief Medical Officer.

“We are thrilled to welcome Arjun and Cyndi to the Compass team. They are highly accomplished leaders with decades of commercial and clinical development experience,” said Thomas Schuetz, MD, PhD, Compass CEO and Board Vice Chairman.

Read the news release at cmpx.info/appointments.

12/17/2025

Sessions for this conference will begin on Monday, January 12, 2026. Please return then to listen to the audio stream of this session.

Address

80 Guest Street, Suite 601
Boston, MA
02135

Website

http://www.compasstherapeutics.com/

Alerts

Be the first to know and let us send you an email when Compass Therapeutics, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Compass Therapeutics, Inc.:

Shortcuts

Want your business to be the top-listed Engineering Company in Boston?